Completed Primary Immunisations by 12 months

Quarter*	Year	No. in cohort	***DTaP/IPV/Hib/HepB	MenC	PCV2	PCV1	Rota2	MenB2
Jan-Mar	2011	6066	97.4%	97.3%	97.5%	~	~	~
Apr-June	2011	6089	97.3%	97.2%	97.4%	~	~	~
July-Sept	2011	6515	97.4%	97.4%	97.5%	~	~	~
Oct-Dec	2011	6557	97.5%	97.3%	97.6%	~	~	~
Jan-Mar	2012	6145	97.2%	97.0%	97.1%	~	~	~
Apr-June	2012	6022	97.3%	97.3%	97.5%	~	~	~
July-Sept	2012	6563	97.3%	97.3%	97.4%	~	~	~
Oct-Dec	2012	6253	97.4%	97.3%	97.4%	~	~	~
Jan-Mar	2013	6195	97.4%	97.4%	97.4%	~	~	~
Apr-June	2013	6165	97.7%	97.7%	97.7%	~	~	~
July-Sept	2013	6394	97.4%	96.8%	97.4%	~	~	
Oct-Dec	2013	6382	97.2%	94.1%	97.2%	~	~	~
Jan-Mar	2013	5784	96.7%	**n/a	96.8%	~	~	~
		5869		**n/a			~	
Apr-June	2014		97.0%		96.8%	~		~
July-Sept	2014	6431	97.6%	98.6%	97.6%	~	94.3%	~
Oct-Dec	2014	5923	97.9%	98.6%	97.8%	~	94.9%	~
Jan-Mar	2015	5854	97.5%	98.5%	97.5%	~	94.8%	~
Apr-June	2015	5920	97.4%	98.4%	97.3%	~	94.9%	~
July-Sept	2015	6439	97.2%	98.2%	97.1%	~	94.1%	~
Oct-Dec	2015	6104	97.3%	98.2%	97.4%	~	94.3%	~
Jan-Mar	2016	5712	97.1%	98.4%	97.1%	~	94.8%	~
Apr-June	2016	5891	96.7%	97.8%	96.7%	~	94.2%	~
July-Sept	2016	6469	97.1%	97.8%	97.1%	~	94.5%	96.0%
Oct-Dec	2016	6206	96.6%	97.3%	96.7%	~	94.3%	95.7%
Jan-Mar	2017	5752	96.9%	90.4%	97.0%	~	95.1%	96.5%
Apr-June	2017	5981	96.7%	~	96.8%	~	94.8%	96.3%
July-Sept	2017	6312	96.6%	~	96.8%	~	94.5%	96.3%
Oct-Dec	2017	6057	96.3%	~	96.5%	~	93.9%	96.2%
Jan-Mar	2018	5649	95.5%	~	95.8%	~	93.7%	95.4%
Apr-June	2018	5587	95.1%	~	95.4%	~	93.6%	95.2%
July-Sept	2018	6073	94.5%	~	94.9%	~	92.3%	94.7%
Oct-Dec	2018	5844	94.0%	~	94.4%	~	92.2%	94.1%
Jan-Mar	2019	5364	94.2%	~	94.5%	~	91.9%	94.1%
Apr-June	2019	5728	93.8%	~	94.1%	~	91.6%	93.9%
July-Sept	2019	6007	94.0%	~	94.4%	~	91.3%	94.2%
Oct-Dec	2019	5694	95.0%	~	95.3%	~	92.1%	95.0%
Jan-Mar	2020	5411	94.8%	~	95.3%	~	92.6%	95.0%
Apr-June	2020	5505	94.9%	~	95.4%	~	93.0%	95.1%
July-Sept	2020	5954	94.5%	~	94.9%	~	92.5%	94.6%
Oct-Dec	2020	5591	93.7%	~	93.5%	~	91.7%	94.0%
Jan-Mar	2021	5344	94.3%	~	~	96.0%	92.3%	94.4%
Apr-June July-Sept	2021 2021	5185 5647	93.6% 93.3%	~	~	95.7% 95.0%	91.6% 90.2%	93.9% 93.6%
Oct-Dec	2021	5352	93.7%	~	~	95.3%	91.1%	94.0%
Jan-Mar	2021	5160	93.2%	~	~	94.9%	91.5%	93.4%
Apr-June	2022	5243	92.0%	~	~	94.2%	90.1%	92.3%
July-Sept	2022	5916	91.2%	~	~	93.8%	88.5%	91.3%
Oct-Dec	2022	5581	92.5%	~	~	94.6%	88.8%	92.8%
Jan-Mar	2023	5092	92.4%	~	~	94.6%	89.7%	92.6%
Apr-June	2023	5046	91.6%	~	~	94.0%	89.4%	91.7%
Jul-Sept	2023	5400	92.5%	~	~	94.6%	89.1%	92.4%
Oct-Dec	2023	5133	92.0%	~	~	94.6%	89.4%	91.9%
Jan-Mar	2024	4838	91.0%	~	~	94.1%	88.6%	91.2%

***DTaP/IPV/Hib/HepB

Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting of vaccine commenced July-September 2018 Dip3 = Tet3 = Pert3 = Pol (IPV)3 =

Hib3 = HepB3 =

Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017 ~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017 Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006) MenC =

PCV2 =

PCV1=

Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)
Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birthday).
This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (on or after the first birthday)).
Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaulated
Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013)
Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)

Rota2 = MenB2 =

^{*} children were 12 months old during the quarter
** accurate Men C coverage at 12 months not available (n/a) due to a software change

Quarter*	Year	No. in cohort *	**DTaP/IPV/Hib/HepB	MenC	PCV2	PCV1	Rota2	MenB2
Jan-Mar	2011	1076	95.6%	95.4%	95.5%	~	~	~
Apr-June	2011	1149	95.3%	95.0%	95.4%	~	~	~
July-Sept	2011	1223	95.0%	95.1%	95.3%	~	~	~
Oct-Dec	2011	1317	94.8%	94.5%	95.3%	~	~	~
Jan-Mar	2012	1157	95.1%	94.7%	95.3%	~	~	~
Apr-June	2012	1099	95.5%	95.2%	95.4%	~	~	~
July-Sept	2012	1270	96.0%	96.1%	96.1%	~	~	~
Oct-Dec	2012	1216	95.2%	95.0%	95.2%	~	~	~
Jan-Mar	2012	1231	95.0%	95.0%	95.2%	~	~	~
Apr-June	2013	1169	95.2%	95.2%	95.5%	~	~	~
						~	~	~
July-Sept	2013	1213	93.7%	93.1%	94.1%			
Oct-Dec	2013	1234	94.7%	90.6%	94.7%	~	~	~
Jan-Mar	2014	1117	93.4%	**n/a	93.6%	~	~	~
Apr-June	2014	1120	94.1%	**n/a	93.6%	~	~	~
July-Sept	2014	1263	95.9%	97.7%	96.0%	~	93.0%	~
Oct-Dec	2014	1131	95.2%	97.1%	95.2%	~	92.0%	~
Jan-Mar	2015	1101	95.8%	97.8%	95.8%	~	93.7%	~
Apr-June	2015	1149	95.5%	97.6%	95.3%	~	93.3%	~
July-Sept	2015	1198	94.4%	97.4%	94.2%	~	92.7%	~
Oct-Dec	2015	1151	94.9%	96.5%	95.0%	~	93.0%	~
Jan-Mar	2016	1113	94.6%	97.3%	95.1%	~	94.0%	~
Apr-June	2016	1108	94.0%	95.4%	94.0%	~	92.0%	~
July-Sept	2016	1157	93.9%	95.7%	94.0%	~	92.0%	92.6%
Oct-Dec	2016	1140	93.5%	95.5%	93.5%	~	92.5%	92.7%
Jan-Mar	2017	1062	94.3%	87.8%	94.5%	~	93.9%	94.3%
Apr-June	2017	1103	93.0%	~	93.3%	~	90.6%	92.7%
July-Sept	2017	1187	94.3%	~	94.3%	~	92.8%	93.9%
Oct-Dec	2017	1196	94.1%	~	94.1%	~	92.6%	93.8%
Jan-Mar	2018	1057	92.4%	~	92.7%	~	93.3%	92.2%
Apr-June	2018	990	89.4%	~	89.8%	~	91.0%	89.6%
July-Sept	2018	1083	89.4%	~	90.1%	~	89.3%	89.6%
Oct-Dec	2018	1087	86.6%		87.3%	~	86.3%	86.7%
Jan-Mar				~				
	2019	1009	88.7%	~	89.3%	~	88.4%	88.6%
Apr-June	2019	1056	86.5%	~	87.2%	~	85.7%	86.9%
July-Sept	2019	1173	87.7%	~	88.7%	~	86.7%	88.5%
Oct-Dec	2019	1066	89.4%	~	90.1%	~	88.5%	90.0%
Jan-Mar	2020	989	90.0%	~	90.4%	~	89.9%	90.4%
Apr-June	2020	1052	90.5%	~	91.1%	~	90.4%	90.8%
July-Sept	2020	1138	89.9%	~	89.9%	~	89.0%	89.6%
Oct-Dec	2020	1061	87.7%	~	87.8%	~	86.6%	88.1%
Jan-Mar	2021	987	89.9%	~	~	92.3%	88.8%	90.0%
Apr-June	2021	985	88.9%	~	~	94.3%	89.5%	89.4%
Jul-Sept	2021	1044	87.9%	~	~	90.4%	85.3%	88.3%
Oct-Dec	2021	998	87.2%	~	~	91.3%	85.6%	88.1%
Jan-Mar	2022	987	85.5%	~	~	90.0%	86.8%	85.8%
Apr-June	2022	927	82.1%	~	~	87.8%	83.2%	83.3%
July-Sept	2022	1099	84.0%	~	~	89.2%	83.4%	84.3%
Oct-Dec	2022	1028	84.9%	~	~	89.4%	82.1%	85.8%
Jan-Mar	2023	878	88.0%		-	91.9%	85.3%	88.5%
Apr-June	2023	919	86.0%	_	~	89.9%	84.1%	86.1%
Jul-Sept	2023	1007	86.8%	~	~	90.8%	84.1%	86.9%
Oct-Dec	2023	933	88.9%				86.9%	88.6%
Jan-Mar	2023			~	~	93.0%		
	2024	895	86.4%	~	~	92.0%	85.9%	86.5%

^{**} accurate Men C coverage at 12 months not available (n/a) due to a software change

***DTaP/IPV/Hib/HepB

Dip3 = Tet3 = Pert3 = Pol (IPV)3 = Hib3 = HepB3 = B
Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting of vaccine commenced July-September 2018

MenC =

PCV2 = PCV1=

Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017

- Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017

Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birthday).

This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (on or after the first birthday)).

Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaulated

Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013)

Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)

Rota2 = MenB2 =

Vaccination Coverage Statistics for Children in SEHSCT: Completed Primary Immunisations by 12 months

Quarter*	Year	No. in cohort	***DTaP/IPV/Hib/HepB	MenC	PCV2	PCV1	Rota2	Mei
Jan-Mar	2011	1088	97.0%	97.0%	97.2%	~	~	-
Apr-June	2011	1102	97.2%	96.9%	97.3%	~	~	-
July-Sept	2011	1175	97.7%	97.7%	98.0%	~	~	
Oct-Dec	2011	1181	97.5%	97.3%	97.5%	~	~	
Jan-Mar	2012	1077	96.8%	96.8%	96.8%	~	~	
Apr-June	2012	1114	97.8%	97.8%	97.8%	~	~	
July-Sept	2012	1235	96.4%	96.3%	96.3%	~	~	
Oct-Dec	2012	1148	97.1%	97.1%	97.5%	~	~	
Jan-Mar	2013	1153	97.3%	97.4%	97.7%	~	~	
Apr-June	2013	1106	98.6%	98.6%	98.6%	~	~	
July-Sept	2013	1106	97.4%	97.0%	97.5%	~	~	
Oct-Dec	2013	1148	97.4%	95.0%	97.6%	~	~	
Jan-Mar	2013	1074	96.3%	**n/a	96.5%	~	~	
Apr-June	2014	1076	97.8%	**n/a	97.9%	~	~	
	2014	1155	97.8%	99.0%	97.9%	~	93.1%	
July-Sept								
Oct-Dec	2014	1020	97.6%	98.6%	97.7%	~	95.4%	
Jan-Mar	2015	1054	97.2%	98.3%	97.3%	~	94.2%	
Apr-June	2015	1050	97.6%	98.5%	97.5%	~	95.0%	
July-Sept	2015	1188	97.1%	97.9%	97.3%	~	94.5%	
Oct-Dec	2015	1054	97.2%	98.1%	97.2%	~	93.7%	
Jan-Mar	2016	1011	97.6%	98.2%	97.5%	~	94.9%	
Apr-June	2016	1073	96.1%	97.9%	96.3%	~	94.7%	
July-Sept	2016	1209	97.5%	97.9%	97.4%	~	95.1%	96
Oct-Dec	2016	1093	97.3%	97.8%	97.3%	~	95.2%	96
Jan-Mar	2017	1046	97.3%	90.1%	97.4%	~	94.0%	96
Apr-June	2017	1094	96.3%	~	96.6%	~	94.4%	96
July-Sept	2017	1127	96.6%	~	96.7%	~	94.9%	96
Oct-Dec	2017	1043	96.4%	~	96.4%	~	94.7%	96
Jan-Mar	2018	1022	95.7%	~	96.2%	~	93.9%	96
Apr-June	2018	963	95.5%	~	95.8%	~	93.1%	95
July-Sept	2018	1026	95.1%	~	95.5%	~	91.9%	95
Oct-Dec	2018	1031	95.0%	~	95.1%	~	92.0%	95
Jan-Mar	2019	968	95.1%	~	95.5%	~	91.3%	95
Apr-June	2019	1017	95.6%	~	95.8%	~	92.7%	95
July-Sept	2019	1078	94.2%	~	94.6%	~	91.5%	94
Oct-Dec	2019	1020	96.6%	~	96.7%	~	93.0%	96
Jan-Mar	2020	946	94.8%	~	94.7%	~	92.4%	94
Apr-June	2020	998	94.0%	~	94.7%	~	92.7%	94
	2020	1044	94.0%	~	95.0%	~	92.7%	94
July-Sept								
Oct-Dec	2020	940	91.8%	~	91.6%	~	90.2%	92
Jan-Mar	2021	950	93.7%	~	~	96.6%	92.7%	94
Apr-June	2021	883	91.3%	~	~	93.7%	88.8%	91
July-Sept	2021	1014	91.4%	~	~	93.4%	88.2%	91
Oct-Dec	2021	903	92.2%	~	~	93.7%	89.9%	92
Jan-Mar	2022	878	92.3%	~	~	93.5%	90.3%	92
Apr-June	2022	941	90.5%	~	~	92.9%	89.8%	90
July-Sept	2022	1035	89.1%	~	~	90.8%	86.8%	89
Oct-Dec	2022	1024	92.1%	~	~	93.4%	87.5%	92
Jan-Mar	2023	934	88.2%	~	~	91.8%	86.3%	88
Apr-June	2023	883	89.1%	~	~	92.8%	87.9%	88
Jul-Sept	2023	973	91.1%	~	~	93.8%	87.8%	90
Oct-Dec	2023	889	90.8%	~	~	93.6%	87.9%	90
Jan-Mar	2024	870	89.0%	~	~	92.0%	87.2%	89

^{**} accurate Men C coverage at 12 months not available (n/a) due to a software change

***DTaP/IPV/Hib/HepB

MenC =

Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting of vaccine commenced July-September 2018 Dip3 = Tet3 = Pert3 =

Pol (IPV)3 = Hib3 = HepB3 =

PCV2 = PCV1=

Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017

- Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017

Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birthday).

This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (on or after the first birthday)).

Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaulated

Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013)

Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)

Rota2 =

MenB2 =

Quarter*

Jan-Mar

No. in cohort ***DTaP/IPV/Hib/HepB

Apr-June	2011	1466	97.9%	97.9%	98.0%	~	~	~
July-Sept	2011	1562	97.3%	97.3%	97.2%	~	~	~ ~
Oct-Dec	2011	1554	98.1%	97.9%	98.3%		_	~
Jan-Mar	2012	1483	97.6%	97.4%	97.4%	~	_	~
Apr-June	2012	1476	96.8%	96.7%	97.0%	~	-	~
	2012	1535				~	~	~ ~
July-Sept Oct-Dec	2012	1458	97.5%	97.1% 97.9%	97.5% 98.0%	~	~	
			97.9%			~	~	~
Jan-Mar	2013	1446	97.6%	97.4%	97.5%	~	~	~
Apr-June	2013	1448	97.3%	97.2%	97.2%	~	~	~
July-Sept	2013	1536	98.1%	97.1%	97.9%	~	~	~
Oct-Dec	2013	1521	97.6%	94.3%	97.6%	~	~	~
Jan-Mar	2014	1395	97.6%	**n/a	97.6%	~	~	~
Apr-June	2014	1432	96.2%	**n/a	96.2%	~	~	~
July-Sept	2014	1538	97.7%	98.8%	97.6%	~	95.7%	~
Oct-Dec	2014	1432	98.5%	98.8%	98.3%	~	94.8%	~
Jan-Mar	2015	1416	97.7%	98.8%	97.7%	~	95.1%	~
Apr-June	2015	1388	97.9%	98.8%	98.0%	~	95.9%	~
July-Sept	2015	1547	97.6%	98.1%	97.4%	~	94.1%	~
Oct-Dec	2015	1504	98.4%	98.9%	98.3%	~	94.9%	~
Jan-Mar	2016	1374	97.5%	98.4%	97.5%	~	95.0%	~
Apr-June	2016	1425	97.9%	98.9%	98.0%	~	95.1%	~
July-Sept	2016	1523	98.2%	98.8%	98.2%	~	95.3%	97.2%
Oct-Dec	2016	1486	97.2%	97.7%	97.2%	~	94.7%	95.9%
Jan-Mar	2017	1323	97.6%	90.6%	97.5%	~	96.1%	97.0%
Apr-June	2017	1426	97.4%	~	97.4%	~	96.1%	97.0%
July-Sept	2017	1488	96.8%	~	97.1%	~	95.4%	96.6%
Oct-Dec	2017	1472	96.9%	~	97.1%	~	95.0%	96.7%
Jan-Mar	2018	1364	96.0%	~	96.2%	~	93.8%	95.8%
Apr-June	2018	1326	95.6%	~	96.3%	~	93.7%	96.2%
July-Sept	2018	1496	95.3%	~	95.7%	~	92.6%	95.5%
Oct-Dec	2018	1400	96.3%	~	96.6%	~	94.4%	96.4%
Jan-Mar	2019	1228	95.4%	~	95.4%	~	92.8%	95.2%
Apr-June	2019	1361	95.3%	~	95.5%	~	94.1%	95.3%
July-Sept	2019	1381	95.7%	~	95.9%	~	93.3%	95.5%
Oct-Dec	2019	1340	96.6%	~	97.1%	~	93.8%	96.9%
Jan-Mar	2020	1302	96.5%	~	96.7%	~	94.0%	96.3%
Apr-June	2020	1302	97.2%	~	97.6%	~	95.7%	97.5%
			95.8%					96.0%
July-Sept	2020	1418		~	96.1%	~	94.1%	
Oct-Dec	2020	1359	95.6%	~	95.5%	~	94.6%	95.7%
Jan-Mar	2021	1257	96.2%	~	~	96.7%	92.9%	96.1%
Apr-June	2021	1283	95.6%	~	~	96.8%	93.4%	95.8%
July-Sept	2021	1382	95.6%	~	~	97.0%	92.8%	95.9%
					~			97.8%
Oct-Dec	2021	1268	97.8%	~		98.3%	94.9%	
Jan-Mar	2022	1209	95.8%	~	~	96.6%	93.5%	96.0%
Apr-June	2022	1282	95.8%	~	~	97.6%	93.5%	95.9%
July-Sept	2022	1368	94.1%	~	~	96.3%	91.3%	93.6%
Oct-Dec	2022	1313	94.6%	~	~	95.7%	90.9%	94.4%
Jan-Mar	2023	1234	94.9%	~	~	96.7%	92.0%	94.9%
Apr-June	2023	1222	93.9%	~	~	95.6%	91.8%	94.1%
Jul-Sept	2023	1324	94.6%	~	~	96.1%	91.4%	94.5%
Oct-Dec	2023	1265	94.3%	~	~	96.4%	92.2%	94.3%
Jan-Mar	2024	1140	92.5%	_	~	95.2%	90.5%	92.8%
						33.270	30.576	32.070
accurate Men C	coverage at 12	months not av	ailable (n/a) due to a	software cha	ange			
DTaP/IPV/Hib/He	рВ							
p3 =	Diphtheria ((DTaP/IPV/Hib3	vaccine) (3 doses)	eplaced with	(DTaP/IPV	//Hib/HepB3	vaccine) f	rom August 2017
t3 =			ccine) (3 doses) rep					
ert3 =			accine) (3 doses) r					
	,		ine) (3 doses) replac	•	•	•	,	•
I (IPV)3 =	\- I ui		, , , , ,	•		•		•
ol (IPV)3 = b3 =	Haemonhili	us Influenzae tv	/pe b (DTaP/IPV/Hih	3 vaccine) (3	doses) ren	laced with	(DTaP/IPV/	Hib/HepB3 vaccine) from August 2017
ol (IPV)3 = b3 = epB3 =				, ,	, .		•	Hib/HepB3 vaccine) from August 2017 of vaccine commenced July-September 2018

PCV1

Rota2

MenB2

MenC

PCV2

but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017

Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017

Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first the state of the process o

PCV2 =

PCV1=

This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old

Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaulated

Rota2 = Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013)

MenB2 = Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)

Quarter*	Year	No. in cohort	***DTaP/IPV/Hib/HepB	MenC	PCV2	PCV1	Rota2	MenB2
Jan-Mar	2011	1404	98.0%	97.9%	98.1%			
Apr-June	2011	1345	97.8%	97.6%	97.7%			
July-Sept	2011	1479	98.0%	97.7%	97.8%			
Oct-Dec	2011	1440	98.5%	98.4%	98.3%			
Jan-Mar	2012	1373	97.9%	97.7%	97.7%			
Apr-June	2012	1282	98.1%	98.0%	98.4%			
July-Sept	2012	1440	98.1%	98.1%	98.2%			
Oct-Dec	2012	1371	98.0%	97.8%	97.8%			
Jan-Mar	2013	1344	98.6%	98.6%	98.6%			
Apr-June	2013	1412	98.5%	98.6%	98.5%			
July-Sept	2013	1520	98.6%	98.0%	98.4%			
Oct-Dec	2013	1411	98.2%	96.0%	98.0%			
Jan-Mar	2014	1297	98.5%	**n/a	98.2%			
Apr-June	2014	1322	98.4%	**n/a	98.3%			
July-Sept	2014	1411	98.4%	98.7%	98.4%		95.6%	
Oct-Dec	2014	1356	99.0%	99.4%	99.0%		96.3%	
Jan-Mar	2015	1341	98.4%	99.0%	98.2%		96.2%	
Apr-June	2015	1367	98.4%	98.5%	98.0%		95.2%	
July-Sept	2015	1407	98.5%	98.8%	98.4%		95.0%	
Oct-Dec	2015	1394	97.8%	98.5%	97.9%		95.1%	
Jan-Mar	2016	1306	97.8%	99.1%	97.7%		95.9%	
Apr-June	2016	1309	97.4%	98.2%	97.7%		95.3%	
	2016	1482	97.6%	98.0%	97.2% 97.4%		95.3%	96.3%
July-Sept Oct-Dec	2016	1462	97.6%	96.0% 97.4%	97.4% 97.6%		94.7%	96.3%
	2016	1357	97.4%	90.9%	97.6%		94.9%	97.0%
Jan-Mar	2017	1373	98.6%		98.6%		95.5% 96.9%	98.3%
Apr-June July-Sept	2017	1450	97.4%	~	96.6%		96.9% 95.4%	96.3% 96.8%
Oct-Dec		1371		~ ~				
Jan-Mar	2017 2018	1257	97.2% 96.0%		97.5% 96.4%		93.9%	97.0% 95.9%
				~			94.0%	
Apr-June	2018	1360	97.4%	~	97.4%		95.1%	97.0%
July-Sept	2018	1463	96.9%	~	97.0%		94.8%	96.9%
Oct-Dec	2018	1306	96.0%	~	96.2%		94.0%	96.0%
Jan-Mar	2019	1237	96.4%	~	96.6%		93.9%	96.4%
Apr-June	2019	1324	95.4%	~	95.5%		93.6%	95.4%
July-Sept	2019	1399	95.4%	~	95.6%		92.8%	95.4%
Oct-Dec	2019	1341	96.0%	~	96.0%		93.9%	95.6%
Jan-Mar	2020	1241	96.2%	~	96.9%		93.9%	96.5%
Apr-June	2020	1276	96.0%	~	96.5%		94.5%	96.0%
July-Sept	2020	1399	95.9%	~	96.5%		93.3%	96.5%
Oct-Dec	2020	1317	96.1%	~	95.7%		93.3%	96.4%
Jan-Mar	2021	1239	95.4%	~	~	96.8%	93.6%	95.5%
Apr-June	2021	1155	95.2%	~	~	96.1%	92.6%	95.1%
July-Sept	2021	1302	95.1%	~	~	96.6%	92.5%	95.7%
Oct-Dec	2021	1223	94.9%	~	~	96.0%	92.2%	95.2%
Jan-Mar	2022	1194	95.6%	~	~	96.6%	93.9%	95.3%
Apr-June	2022	1209	93.5%	~	~	94.6%	90.3%	93.6%
July-Sept	2022	1408	93.1%	~	~	95.5%	89.3%	93.0%
Oct-Dec	2022	1296	94.8%	~	~	97.1%	92.1%	94.8%
Jan-Mar	2023	1211	94.7%	~	~	95.6%	92.1%	95.0%
Apr-June	2023	1194	94.1%	~	~	95.6%	91.5%	94.1%
Jul-Sept	2023	1241	93.6%	~	~	95.2%	90.9%	93.2%
Oct-Dec	2023	1183	92.5%	~	~	94.4%	89.8%	92.3%
Jan-Mar	2024	1124	93.4%	~	~	95.2%	90.8%	93.3%

^{**} accurate Men C coverage at 12 months not available (n/a) due to a software change

***DTaP/IPV/Hib/HepB

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tet3 = Pert3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Pol (IPV)3 =

Hib3 = HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting of vaccine commenced July-September 2018

MenC = Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017 ~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017

PCV2 = Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

PCV1= Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birt

This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (c

Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaulated

Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013) Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015) Rota2 = MenB2 =

Completed Primary Immunisations by 12 months

Quarter*	Year	No. in cohort	***DTaP/IPV/Hib/HepB	MenC	PCV2	PCV1	Rota2	Men
Jan-Mar	2011	1056	98.2%	98.1%	98.3%	~	~	~
Apr-June	2011	1027	98.3%	98.2%	98.3%	~	~	~
July-Sept	2011	1076	99.3%	99.3%	99.3%	~	~	~
Oct-Dec	2011	1065	98.4%	98.4%	98.3%	~	~	~
Jan-Mar	2012	1055	98.3%	98.3%	98.3%	~	~	~
Apr-June	2012	1051	98.7%	98.7%	98.7%	~	~	~
July-Sept	2012	1083	98.8%	99.0%	98.8%	~	~	~
Oct-Dec	2012	1060	98.6%	98.6%	98.6%	~	~	~
Jan-Mar	2013	1021	98.3%	98.1%	98.1%	~	~	~
Apr-June	2013	1030	98.9%	99.0%	98.9%	~	~	~
July-Sept	2013	1019	98.9%	98.7%	98.9%	~	~	~
Oct-Dec	2013	1068	97.9%	94.5%	97.9%	~	~	~
Jan-Mar	2013	901	97.8%	**n/a	97.8%	~	~	~
Apr-June	2014	919	98.6%	**n/a	98.6%	~	~	~
		1064	98.3%			~		
July-Sept	2014			98.7%	98.3%		93.6%	~
Oct-Dec	2014	984	98.6%	99.2%	98.5%	~	96.1%	~
Jan-Mar	2015	942	97.9%	98.7%	98.1%	~	94.6%	~
Apr-June	2015	966	97.5%	98.9%	97.6%	~	94.5%	~
July-Sept	2015	1099	97.9%	98.9%	97.9%	~	94.4%	~
Oct-Dec	2015	1001	98.0%	98.8%	98.1%	~	94.3%	~
Jan-Mar	2016	908	98.0%	99.1%	98.0%	~	94.1%	~
Apr-June	2016	976	97.6%	98.0%	97.4%	~	93.1%	~
July-Sept	2016	1098	98.2%	98.5%	98.0%	~	94.9%	96.4
Oct-Dec	2016	1045	97.3%	97.9%	97.4%	~	93.8%	96.3
Jan-Mar	2017	964	97.3%	92.6%	97.8%	~	95.4%	97.3
Apr-June	2017	985	97.6%	~	97.4%	~	95.1%	96.5
July-Sept	2017	1060	98.0%	~	98.3%	~	93.2%	97.7
Oct-Dec	2017	975	96.7%	~	97.3%	~	93.2%	97.3
Jan-Mar	2017	949	97.0%	~	97.2%	~	93.2%	96.9
Apr-June	2018	949	96.6%	~	96.6%	~	93.2%	96.6
July-Sept	2018	1005	94.9%	~	95.3%	~	91.6%	95.2
Oct-Dec	2018	1020	95.4%	~	95.9%	~	93.0%	95.9
Jan-Mar	2019	922	94.8%	~	95.2%	~	92.2%	94.5
Apr-June	2019	970	95.9%	~	96.1%	~	90.3%	95.7
July-Sept	2019	976	97.0%	~	97.4%	~	91.7%	97.3
Oct-Dec	2019	927	95.8%	~	96.5%	~	90.5%	96.0
Jan-Mar	2020	933	95.7%	~	96.8%	~	92.2%	96.6
Apr-June	2020	877	96.4%	~	96.9%	~	90.5%	96.8
July-Sept	2020	955	96.1%	~	96.4%	~	92.9%	95.6
Oct-Dec	2020	915	96.1%	~	95.7%	~	92.6%	96.4
Jan-Mar	2021	911	95.7%	~	~	97.5%	93.2%	95.6
Apr-June	2021	879	96.1%	~	~	97.3%	92.7%	97.0
July-Sept	2021	905	95.4%	~	~	96.4%	90.9%	95.8
Oct-Dec	2021	960	95.0%	~	~	96.0%	91.8%	95.0
Jan-Mar	2021	892	95.9%	~	~	97.1%		96.7
				~			91.7%	
Apr-June	2022	884	96.2%		~	97.1%	92.5%	96.0
July-Sept	2022	1006	94.7%	~	~	96.3%	90.7%	94.9
Oct-Dec	2022	920	95.2%	~	~	96.6%	90.2%	95.8
Jan-Mar	2023	835	94.9%	~	~	96.2%	91.0%	94.5
Apr-June	2023	828	93.4%	~	~	95.3%	90.3%	93.8
Jul-Sept	2023	855	95.8%	~	~	97.1%	89.6%	96.1
Oct-Dec	2023	863	92.8%	~	~	94.9%	89.0%	92.8
Jan-Mar	2024	809	92.6%	~	~	95.7%	87.3%	93.4

^{**} accurate Men C coverage at 12 months not available (n/a) due to a software change

***DTaP/IPV/Hib/HepB

Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Haemophilus Influenzae type b (DTaP/IPV/Hib/3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting of vaccine commenced July-September 2018 Dip3 = Tet3 = Pert3 =

Pol (IPV)3 = Hib3 = HepB3 =

MenC = Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016

but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017
~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017
Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

PCV2 =

PCV1=

Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birthday).

This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (on or after the first birthday).

Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaulated

Rota2 = MenB2 = Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013) Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)